Role of intestinal flora on the antitumor immunity of oncolytic viruses

2021 Fiscal Year Final Research Report

• Project/Area Number: 19H03434
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 49010:Pathological biochemistry-related
• Research Institution: Nagoya University
• Principal Investigator: Naoe Yoshinori 名古屋大学, 医学系研究科, 特任准教授 (50392048)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 腫瘍溶解性ウイルス / C-REV / 腸内細菌叢 / 抗生物質

Outline of Final Research Achievements

Changes in the intestinal flora were observed by administration of C-REV to antibiotic-treated mice in the intraperitoneal transplant model and the subcutaneous transplant model. The antitumor effect of C-REV changes depending on the combination of the four antibiotics Ampicillin (A), Metronidazole (M), Neomycin (N), or Vancomycin (V), and the order of the effect is (large effect) AMNV = AMV > MNV > ANV = AMN (small effect). The difference in the bacterial flora of the mice by the antibiotic cocktail treatment was found, and a large change was observed in the bacterial flora with and without the antibiotic cocktail treatment.

Free Research Field

免疫学

Academic Significance and Societal Importance of the Research Achievements

腸内細菌叢の変化により化学療法、免疫チェックポイント阻害剤の抗腫瘍効果が変化することが報告されているが、腫瘍溶解性ウイルスの抗腫瘍効果が変化するかは不明であった。今回の研究結果から抗生剤処理により腫瘍溶解性ウイルスの抗腫瘍効果が変化することを見出し、その抗腫瘍効果の変化に腸内細菌叢が関与する結果を得た。